NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that 20 abstracts, including 18 which contain new investigational data from studies on ORENCIA® (abatacept) in patients with rheumatoid arthritis or lupus nephritis, will be presented at the American College of Rheumatology (ACR) Annual Scientific Meeting in Chicago November 5-9.
